DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Ovarian Cancer Pipeline Highlights - 2016 Update" drug pipelines to their offering.
Ovarian Cancer Pipeline Highlights - 2016 Update, provides most up-to-date information on key pipeline products in the global Ovarian Cancer market. It covers emerging therapies for Ovarian Cancer in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Scope of the Report
Clinical Trial Stages:
The report provides Ovarian Cancer pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Ovarian Cancer pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.
Company:
The report provides Ovarian Cancer pipeline products by the company.
Short-term Launch Highlights:
Find out which Ovarian Cancer pipeline products will be launched in the US and Ex-US till 2019.
Key Topics Covered:
1. Ovarian Cancer Pipeline by Stages
2. Ovarian Cancer Pipeline by Drug Class
3. Ovarian Cancer Pipeline by Company
4. Ovarian Cancer Phase 3 Clinical Trial Insights
5. Ovarian Cancer Phase 2 Clinical Trial Insights
6. Ovarian Cancer Phase 1 Clinical Trial Insights
7. Ovarian Cancer Preclinical Research Insights
8. Ovarian Cancer Discovery Stage Insights
9. Appendix
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/b7b5wm/ovarian_cancer
